Table 2.
Retrospective studies.
| Authors (reference) | Journal/year | Patients (OS) | Gender (% male) | Age (range) | Quantification indexes |
|---|---|---|---|---|---|
| Nair et al. [27] | Clin Positron Imaging/2000 | 16 (16) | 47 | 15–29 | TBR, %TBR |
| Franzius et al. [28] | Clin Nucl Med/2000 | 17 (11) | 76 | 5–36 | T : NT-ratio |
| Hawkins et al. [29] | Cancer/2002 | 33 (18) | 67 | 6–19 | SUV, SUV-ratio |
| Iagaru et al. [30] | Clin Nucl Med/2008 | 14 (7) | 57 | 18–56 | SUV, SUV-ratio |
| Mahajan et al. [31] | Pediatr Blood Cancer/2008 | 39 (39) | 49 | 6–20 | SUV |
| Costelloe et al. [32] | J Nucl Med/2009 | 31 (31) | 61 | 9–65 | SUV, TLG, %TLG |
| Piperkova et al. [33] | Clin Nucl Med/2009 | 83 (NR) | NR | NR | SUV |
| Hamada et al. [34] | Ann Nucl Med/2009 | 11 (11) | 64 | 10–68 | SUV, SUV-ratio |
| Hawkins et al. [35] | Cancer/2009 | 40 (40) | NR | 7–31 | SUV, SUV-ratio |
| Gaston et al. [36] | Skeletal Radiol/2011 | 31 (19) | 42 | 14–38 | SUV, SUV-ratio, MTV, %ID |
| Kim et al. [11] | Cancer Res Treat/2011 | 23 (13) | 69 | 3–19 | SUV, SUV-ratio |
| London et al. [37] | Pediatr Radiol/2012 | 8 (5) | NR | NR | SUV |
SUV: standardized uptake value; T: NT-ratio: tumour to nontumour ratio; TBR: tumour-to-background ratio; TLG: total lesion glycolysis; %TBR: percent change in TBR (baseline to posttherapy); %TLG: percent change in TLG (baseline to posttherapy); MTV: metabolic tumour volume; %ID: percent injected dose retained within the lesion; NR: not reported.